Natural history of progression after PSA elevation following radical prostatectomy

Journal of the American Medical Association

Volumn 281, Issue 17, 1999, Pages 1591-1597

  Pound, Charles R ^a   Partin, Alan W ^a,c   Eisenberger, Mario A ^a   Chan, Daniel W ^a   Pearson, Jay D ^b   Walsh, Patrick C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; FINGER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECTUM; RETROSPECTIVE STUDY;

DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0033526309     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.17.1591     Document Type: Article

References (32)

1. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395-406.
2. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152:1850-1857.
3. Trapasso JG, DeKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994:152:1821-1825.
4. Catalona WJ, Smith DS. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837-1842.
5. Ohori M, Goad JR, Wheeler TM, et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994;152:1843-1849.
6. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer: multi-institutional pooled analysis. JAMA. 1996;276:615-619.
7. Krongrad A, Lai HL, Lai S. Survival after radical prostatectomy. JAMA. 1997;278:44-46.
8. Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostate cancer. Cancer. 1993;72:310-322.
9. Lepor H, Kimball AW, Walsh PC. Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol. 1989;141:82-84.
10. Gibbons RP, Correa RJ, Brannen GE, Weissman RM. Total prostatectomy for clinically localized prostate cancer: long-term results. J Urol. 1989;141:564-566.
11. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993;20:713-725.
12. Scher HI, Curley T, Yeh S, Iverson JM, O'Dell M, Larsor SM. Therapeutic alternatives for hormone-refractory prostatic cancer. Semin Urol. 1992;10:55-64.
13. Patel A, Dorey F, Franklin J, DeKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441-1445.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
15. Bauer JJ, Connelly RR, Sesterhenn IA, et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer. 1997;79:952-962.
16. Veltri RW, O'Dowd GJ, Orozco R, Miller MC. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the pre-operative prediction of prostate cancer staging and prognosis. Semin Urol Oncol.1998;16:106-117.
17. Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995;45:831-838.
18. Dillioglugil O, Leibman BD, Kattan MW, et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997; 50:93-99.
19. Zincke H, Bergstralh EJ, Larson-Keller JJ, et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer. 1992;70 (suppl1):311-323.
20. Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol. 1994;152:1077-1081.
21. Golimbu M, Provet J, Al-Askari S. Radical prostatectomy for stage D1 prostate cancer. Urology. 1987; 30:427-435.
22. Partin AW, Pearson, JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 1994;43:649-659.
23. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer. 1990;66 (suppl5):1017-1021.
24. Eisenberger MA, Blumenstein BB, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998; 339:1036-1042.
25. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973;32:1126-1130.
26. Kramalowsky EV. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol. 1988;139:1242-1244.
27. Steckel J, DeKernion JB. Therapeutic options for stage D1 prostate cancer. Am Urol Assoc Update Series. 1994;13:166.
28. Byar DP, Corle DK. Hormonal therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies. Natl Cancer Inst Monogr. 1988;7:165-170.
29. Walsh PC. Benign and malignant neoplasms of the prostate. J Urol. 1989;141:1032-1033.
30. Schroder FH. Endocrine treatment of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology. Vol 3. 7th ed. Philadelphia, Pa: WB Saunders Co; 1998:2627-2644.
31. Sharifi R, Soloway M, for the Leuprolide Study Group. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol. 1990;143:68-71.
32. Crawford ED, Eisenberger MA, McLeod DC, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321:419-424.